cerenis.com Report : Visit Site

Technical data of the cerenis.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host cerenis.com. Currently, hosted in France and its service provider is OVH SAS .

the related websites

bloomberg.com batstrading.co.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

please select your page home about cerenis management board of directors steering committee scientific advisory board specialized committees audit committee remuneration committee research committee our approach about hdl and cvd the commercial opportunity the science of hdl hdl deficiency what is hdl deficiency? our therapies cer 001 cer 209 scientific presentation media press releases events cerenis in the media investors regulated information shareholder meeting investor presentations corporate presentation cerenis on stock market investor contacts financial calendar please select your page home about cerenis — management — board of directors — steering committee — scientific advisory board — specialized committees —— audit committee —— remuneration committee —— research committee our approach — about hdl and cvd — the commercial opportunity — the science of hdl hdl deficiency — what is hdl deficiency? our therapies — cer 001 — cer 209 — scientific presentation media — press releases — events — cerenis in the media investors — regulated information — shareholder meeting — investor presentations — corporate presentation — cerenis on stock market — investor contacts — financial calendar bringing hdl breakthroughs to patients the hdl company cerenis therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative hdl therapies for the treatment of cardiovascular and metabolic diseases. hdl is the primary mediator of the reverse lipid transport, or rlt, the only natural pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body. cerenis is developing a portfolio of hdl therapies, including hdl mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as post-acs patients and patients with hdl deficiency, and drugs which increase hdl for patients with low number of hdl particles to treat atherosclerosis and associated metabolic diseases. cerenis is well-positioned to become the leader in the hdl therapeutic market with a broad portfolio of programs in development. what is hdl deficiency? hypoalphalipoproteinemia (“low hdl”), as a general term, has historically been defined clinically as an hdl-cholesterol (hdl-c) less than 40 mg/dl (1.0 mmol/l) in men, and less than 50 mg/dl (1.3 mmol/l) in women. a number of etiologies, often metabolic, can underlie a reduced circulating level of cholesterol in the hdl fraction, for example diabetes, metabolic syndrome, obesity, and lack of physical activity (thus called secondary hypoalphalipoproteinemia). in a very small percentage of the population, particularly among patients with the very lowest hdl-c values, there are patients who have a genetic defect (thus called primary hypoalphalipoproteinemia) affecting either the constituent components of the pre-β particle, the process of pre-β particle synthesis, the steps leading to maturation into an alpha hdl particle, or the rates of catabolism – any of which alone or in combination can then result in an inherited condition of a very low circulating hdl particle number. read more interview with professor jean ferrières , cardiologist at the chu toulouse rangueil hdl workshop conference, san francisco, may 9 2018 presentation slideshow using hdl particles in oncology download here the latest scientific studies related to this subject latest press releases 28/05/2018 cerenis therapeutics and university of north texas health science center announce a strategic initiative to develop new hdl-based pharmaceutical products 07/05/2018 cerenis to attend 2018 hdl workshop (adjacent to atvb|pvd scientific sessions) cerenis in the media 25/02/2016 cerenis/cer-209 dans l’émission intégrale bourse 02/12/2015 jean-louis dasseux, pdg de cerenis therapeutics, invité de l'émission direct marchés contact cerenis therapeutics holding sa 33-43 av. georges pompidou – bât. d2 31130 balma – france tel. +33 5 62 24 97 06 fax +33 5 61 57 34 12 email: [email protected] cerenis therapeutics inc po box 861 lakeland, mi 48143 usa admin i legal notice © 2018 ® cerenis scroll

URL analysis for cerenis.com

https://www.cerenis.com/en///en/about-cerenis
https://www.cerenis.com/en///en/our-therapies/cer-001
https://www.cerenis.com/en///images/pdfs/images/pdfs/pr_cerenis_unthsc_vf_eng.pdf
https://www.cerenis.com/en///en/admin
https://www.cerenis.com/en///images/pdfs/presse/agefi_cerenis_retenu_par_jp_morgan_funds_global_healthcare_26112015.pdf
https://www.cerenis.com/en///en/media-en/cerenis-in-the-media
https://www.cerenis.com/en///images/pdfs/images/pdfs/pr_cerenis_hdlvff.pdf
https://www.cerenis.com/en///en/investors/cerenis-on-stock-market
https://www.cerenis.com/en///./index.php/hdl-deficiency/what-s-hdl-deficiency
https://www.cerenis.com/en///en/media-en/press-releases
https://www.cerenis.com/en///en/about-cerenis/specialized-committees/remuneration-committee
https://www.cerenis.com/en///en/investors/shareholder-meeting
https://www.cerenis.com/en///en/our-therapies/scientific-presentation
https://www.cerenis.com/en///fr/
https://www.cerenis.com/en///en/hdl-deficiency/what-s-hdl-deficiency

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: CERENIS.COM
Registry Domain ID: 146396141_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.networksolutions.com
Registrar URL: http://networksolutions.com
Updated Date: 2015-01-14T08:59:09Z
Creation Date: 2005-03-15T21:16:24Z
Registry Expiry Date: 2020-03-15T20:16:24Z
Registrar: Network Solutions, LLC.
Registrar IANA ID: 2
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.8003337680
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS37.WORLDNIC.COM
Name Server: NS38.WORLDNIC.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-08-12T10:04:44Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Network Solutions, LLC.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =cerenis.com

  PORT 43

  TYPE domain

DOMAIN

  NAME cerenis.com

  CHANGED 2015-01-14

  CREATED 2005-03-15

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  NS37.WORLDNIC.COM 207.204.40.119

  NS38.WORLDNIC.COM 207.204.21.119

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .